What Amgen's latest 10-Q says: 8 signals

Amgen filed its latest 10-Q with the SEC on Aug 4, 2026. It discusses capacity constraint, competitor named and compliance burden.

Public (AMGN)Biotechnology Research10,000+ employeesamgen.comLinkedIn

Filed: Aug 4, 2026
Filings: 2
Signals: 20

10-Q · latest 10

What Amgen's 10-Q filings say

10-Q
Filed Aug 4, 2026 · 8 signals
SEC EDGAR
- Competitor namedNegative
  Prolia & XGEVA sales fall over 30% due to biosimilar competition, losing over $540M in Q2
  Sales for key drugs Prolia and XGEVA plummeted by 32% and 34% respectively in Q2 2026, a combined revenue drop of over $540 million versus prior year.
  $543M
  Combined Q2 YoY revenue decline for Prolia ($363M) and XGEVA ($180M)
  -33%
  Average YoY sales decline for Prolia (-32%) and XGEVA (-34%) in Q2
  biosimilarsgenerics
- Market share lossNegative
  Prolia and XGEVA sales plummet over 30% due to biosimilar competition after patent expiry.
  Amgen is experiencing accelerated sales erosion for two major products, Prolia (sales down 32%) and XGEVA (sales down 34%), due to lower volume and pricing from new biosimilar competitors.
  $363M
  Prolia quarterly sales decline YoY ($1,122M to $759M)
  -32%
  Prolia total sales change YoY for the quarter
- Pricing pressureNegative
  ENBREL net selling price drops 22% due to Medicare price setting under the IRA.
  Government regulation is directly impacting revenue, with ENBREL sales decreasing due to a 22% drop in net selling price from the Inflation Reduction Act (IRA).
  -22%
  ENBREL lower net selling price for the quarter
- Major contract winPositive
  Amgen secures $60M order from U.S. government for Nplate in H1 2026
  Global Nplate sales for the first half of 2026 were significantly boosted by a $60 million order from the U.S.
  $60M
  U.S. government order for Nplate
- Litigation materialNegative
  Company contests IRS demand for an additional $3.6 billion in federal tax.
  Amgen is in U.S. Tax Court over IRS adjustments for years 2010-2012, which could result in a $3.6 billion tax liability, plus interest.
  $3.6B
  Potential additional federal tax from IRS dispute
- Capacity constraintNeutral
  Amgen's new drugs UPLIZNA (+90%) and IMDELLTRA (>100%) see explosive volume growth
  Rapid, volume-driven growth in newer drugs like UPLIZNA and IMDELLTRA is a key strategic success but creates potential operational challenges.
  $335M
  Total UPLIZNA sales for the three months ended June 30, 2026
  90%
  Total UPLIZNA sales change YoY for the three months ended June 30
- Compliance burdenNeutral
  Amgen faces new global tax compliance rules from OECD and U.S. legislation (OB3).
  The company is navigating the enactment of the OECD's global minimum tax agreement and new U.S.
10-Q
Filed Apr 30, 2026 · 12 signals
SEC EDGAR
- Litigation materialNegative
  Facing potential $10.7B+ in back taxes and penalties from ongoing IRS dispute
  Amgen is in U.S. Tax Court contesting IRS claims for approximately $8.7B in additional tax and $2.0B in penalties for the 2010-2015 period.
  $10.7B
  Potential back taxes and penalties from IRS for years 2010-2015
- Competitor namedNegative
  Prolia sales plummet 34% ($372M) due to biosimilar competition after patent expiry.
  Global Prolia sales dropped from $1.1B to $727M year-over-year, driven by a 17% volume loss and lower prices.
  $372M
  Year-over-year decrease in Total Prolia sales for Q1
  -34%
  Year-over-year change in Total Prolia sales for Q1
  biosimilars
- Competitor namedNegative
  XGEVA sales fall 27% ($155M) as biosimilar competition intensifies post-patent.
  Global XGEVA sales declined from $566M to $411M year-over-year due to a 19% drop in volume and lower prices.
  $155M
  Year-over-year decrease in Total XGEVA sales for Q1
  -27%
  Year-over-year change in Total XGEVA sales for Q1
  biosimilars

Showing 10 of 20 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Amgen earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call date	Period	What the company said
Nov 4, 2025	Q3 FY2025	Investing over $2.2B in CapEx for US manufacturing expansion.The company is making massive capital expenditures to expand its manufacturing network capacity, specifically naming sites in Ohio, North Carolina, and California among others. This level of investment signals a large, active budget for construction, industrial equipment, automation, and related operational technology services.
Nov 4, 2025	Q3 FY2025	Planning over $3B in US manufacturing investments this yearThe company is making a massive capital investment into its US-based manufacturing network, creating significant opportunities for vendors in industrial equipment, construction, automation, and operational technology.
Nov 4, 2025	Q3 FY2025	Accelerating AI adoption across the entire value chain.The CFO highlighted a major strategic push to implement AI in R&D, manufacturing optimization, and commercial customer engagement to drive productivity. This signals active projects and budget for AI/ML platforms, data infrastructure modernization, and specialized consulting services.
Nov 4, 2025	Q3 FY2025	Accelerating AI and technology investment across the value chainLeadership is strategically deploying AI and modern data platforms to boost productivity in R&D, manufacturing, and commercial operations. This creates a strong need for AI/ML solutions, data infrastructure, cloud services, and specialized consulting.
Nov 4, 2025	Q3 FY2025	Committing significant investment to advance key late-stage drug programsThe company is explicitly funding the advancement of several high-potential drugs, including MariTide and Olpasiran. This signals spending on clinical trials, regulatory affairs, and pre-commercialization activities, opening doors for related service and technology providers.
Nov 4, 2025	Q3 FY2025	Actively engaging policymakers on innovation and biosimilar market rules.The CEO is focused on influencing policy in Washington regarding drug access, innovation, and the biosimilar market structure. This indicates a potential need for government affairs consulting, policy analysis tools, and public relations support to manage regulatory risk and advocate for their position.

Signal API · MCP

Track Amgen with the Signal API

One POST /v1/companies/enrich call with amgen.com returns Amgen 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"amgen.com","signal_types":["sec-10q"],"limit":20}'

Same industry

Questions about Amgen 10-Q

When did Amgen file its latest 10-Q?

Amgen filed its latest 10-Q on Aug 4, 2026. The one before it was filed on Apr 30, 2026.

What did Amgen disclose in its latest 10-Q?

From the filing dated Aug 4, 2026: Prolia & XGEVA sales fall over 30% due to biosimilar competition, losing over $540M in Q2

What did Amgen say on its recent earnings calls?

Q3 FY2025: Investing over $2.2B in CapEx for US manufacturing expansion. (dated Nov 4, 2025).

Where can I read Amgen's 10-Q filing?

The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/amgn-20260630.htm. This page summarizes what the filing says and links to it.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of Sep 30, 2026.

How this data is built →Get it from the Signal API →

What Amgen's latest 10-Q says: 8 signals

What Amgen's 10-Q filings say

Amgen earnings headlines

Track Amgen with the Signal API

10-Q at related companies

Questions about Amgen 10-Q